|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Procainamide#Adverse Reactions]] |
| {{Propafenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| ===6.1 Clinical Trials Experience===
| |
| | |
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
| |
| | |
| The data described below reflect exposure to RYTHMOL SR 225 mg twice daily in 126 patients, to RYTHMOL SR 325 mg twice daily in 135 patients, to RYTHMOL SR 425 mg twice daily in 136 patients, and to placebo in 126 patients for up to 39 weeks (mean 20 weeks) in a placebo-controlled trial (RAFT) conducted in the US. The most commonly reported adverse events with propafenone (>5% and greater than placebo) excluding those not reasonably associated with the use of the drug or because they were associated with the condition being treated, were [[dizziness]], [[palpitations]], [[chest pain]], [[dyspnea]], taste disturbance, [[nausea]], [[fatigue]], [[anxiety]], [[constipation]], [[upper respiratory tract infection]], [[edema]], and [[influenza]]. The frequency of discontinuation due to adverse events was 17%, and the rate was highest during the first 14 days of treatment.
| |
| | |
| Cardiac-related adverse events occurring in ≥ 2% of the patients in any of the RAFT propafenone SR treatment groups and more common with propafenone than with placebo, excluding those that are common in the population and those not plausibly related to drug therapy, included the following: [[angina pectoris]], atrial flutter, AV block first-degree, [[bradycardia]], congestive [[cardiac failure]], [[cardiac murmur]], [[edema]], [[dyspnea]], [[rales]], [[wheezing]], and cardioactive drug level above therapeutic.
| |
| | |
| Propafenone prolongs the PR and QRS intervals in patients with atrial and ventricular arrhythmias. Prolongation of the QRS interval makes it difficult to interpret the effect of propafenone on the QT interval [see Clinical Pharmacology (12.2)].
| |
| | |
| Non-cardiac related adverse events occurring in ≥2% of the patients in any of the RAFT propafenone SR treatment groups and more common with propafenone than with placebo, excluding those that are common in the population and those not plausibly related to drug therapy, included the following: [[blurred vision]], [[constipation]], [[diarrhea]], dry mouth, [[flatulence]], [[nausea]], [[vomiting]], [[fatigue]], [[weakness]], [[upper respiratory tract infection]], blood alkaline phosphatase increased, [[hematuria]], muscle weakness, [[dizziness ]](excluding [[vertigo]]),[[ headache]], taste disturbance, [[tremor]], [[somnolence]], [[anxiety]], [[depression]], [[ecchymosis]].
| |
| | |
| No clinically important differences in incidence of adverse reactions were noted by age or gender. Too few non-Caucasian patients were enrolled to assess adverse events according to race.
| |
| | |
| Adverse events occurring in 2% or more of the patients in any of the ERAFT [see Clinical Studies (14)] propafenone SR treatment groups and not listed above include the following: bundle branch block left , bundle branch block right, conduction disorders, [[sinus bradycardia]], and [[hypotension]]. | |
| | |
| Other adverse events reported with propafenone clinical trials not already listed elsewhere in the prescribing information include the following adverse events by body system and preferred term.
| |
| | |
| <u>Blood and Lymphatic System Disorders</u>
| |
| | |
| [[Anemia]], [[lymphadenopathy]], [[spleen disorder]], [[thrombocytopenia]].
| |
| | |
| <u>Cardiac Disorders</u>
| |
| | |
| [[Unstable angina]], [[atrial hypertrophy]], [[cardiac arrest]], [[coronary artery disease]], [[extrasystoles]], [[myocardial infarction]], [[nodal arrhythmia]], [[palpitations]], [[pericarditis]],[[sinoatrial block]], [[sinus arrest]], [[sinus arrhythmia]], [[supraventricular extrasystoles]], [[ventricular extrasystoles]], [[ventricular hypertrophy]].
| |
| | |
| <u>Ear and Labyrinth Disorders</u>
| |
| | |
| Hearing impaired, [[tinnitus]], [[vertigo]].
| |
| | |
| <u>Eye Disorders</u>
| |
| | |
| Eye [[hemorrhage]], eye inflammation, [[eyelid ptosis]], [[miosis]], [[retinal disorder]], visual acuity reduced.
| |
| | |
| <u>Gastrointestinal Disorders</u>
| |
| | |
| Abdominal distension, abdominal pain, [[duodenitis]], [[dyspepsia]], [[dysphagia]], [[eructation]], [[gastritis]], [[gastroesophageal reflux disease]], [[gingival bleeding]], [[glossitis]], [[glossodynia]], [[gum pain]], [[halitosis]], [[intestinal obstruction]], [[melena]], mouth ulceration, [[pancreatitis]], [[peptic ulcer]], [[rectal bleeding]], sore throat.
| |
| | |
| <u>General Disorders and Administration Site Conditions</u>
| |
| | |
| Chest pain, feeling hot, [[hemorrhage]], [[malaise]], pain, [[pyrexia]].
| |
| | |
| <u>Hepatobiliary Disorders</u>
| |
| | |
| [[Hepatomegaly]].
| |
| | |
| <u>Investigations</u>
| |
| | |
| Abnormal heart sounds, abnormal pulse, [[carotid bruit]], decreased blood chloride, decreased blood pressure, decreased blood sodium, decreased hemoglobin, decreased neutrophil count, decreased platelet count, decreased prothrombin level, decreased red blood cell count, decreased weight, glycosuria present, increased alanine aminotransferase, increased aspartate aminotransferase, increased blood bilirubin, increased blood cholesterol, increased blood creatinine, increased blood glucose, increased blood lactate dehydrogenase, increased blood pressure, increased blood prolactin, increased blood triglycerides, increased blood urea, increased blood uric acid, increased eosinophil count, increased gamma-glutamyltransferase, increased monocyte count, increased prostatic specific antigen, increased prothrombin level, increased weight, increased white blood cell count, ketonuria present, proteinuria present.
| |
| | |
| <u>Metabolism and Nutrition Disorders</u>
| |
| | |
| [[Anorexia]], [[dehydration]], [[diabetes mellitus]], [[gout]], [[hypercholesterolemia]], [[hyperglycemia]], [[hyperlipidemia]], [[hypokalemia]].
| |
| | |
| <u>Musculoskeletal, Connective Tissue, and Bone Disorders</u>
| |
| | |
| [[Arthritis]], [[bursitis]], [[collagen-vascular disease]], [[costochondritis]], [[joint disorder]], [[muscle cramps]], [[myalgia]], neck pain, pain in jaw, [[sciatica]], [[tendonitis]].
| |
| | |
| <u>Nervous System Disorders</u>
| |
| | |
| [[Amnesia]], [[ataxia]], balance impaired, brain damage, cerebrovascular accident, [[dementia]], [[gait abnormal]], [[hypertonia]], [[hypothesia]], [[insomnia]], [[paralysis]], [[paresthesia]], [[peripheral neuropathy]], [[speech disorder]], [[syncope]], [[tongue hypoesthesia]].
| |
| | |
| <u>Psychiatric Disorder:</u>
| |
| | |
| Decreased libido, emotional disturbance, mental disorder, neurosis, nightmare, sleep disorder.
| |
| | |
| <u>Renal and Urinary Disorders</u>
| |
| | |
| [[Dysuria]], [[nocturia]], [[oliguria]], [[pyuria]], [[renal failure]], [[urinary casts]], [[urinary frequency]], [[urinary incontinence]], [[urinary retention]], [[urine abnormal]].
| |
| | |
| <u>Reproductive System and Breast Disorders</u>
| |
| | |
| Breast pain, [[impotence]], [[prostatism]].
| |
| | |
| <u>Respiratory, Thoracic, and Mediastinal Disorders</u>
| |
| | |
| [[Atelectasis]], breath sounds decreased, chronic obstructive airways disease, [[cough]], [[epistaxis]], [[hemoptysis]], lung disorder, [[pleural effusion]], [[pulmonary congestion]], [[rales]], [[respiratory failure]], [[rhinitis]], [[throat tightness]].
| |
| | |
| <u>Skin and Subcutaneous Tissue Disorders</u>
| |
| | |
| [[Alopecia]], [[dermatitis]], dry skin, [[erythema]], nail abnormality, [[petechiae]], [[pruritus]], sweating increased, [[urticaria]].
| |
| | |
| <u>Vascular Disorders</u>
| |
| | |
| Arterial embolism limb, deep limb venous thrombosis, [[flushing]], [[hematoma]], [[hypertension]], [[hypertensive crisis]], [[hypotension]], labile blood pressure, [[pallor]], peripheral coldness, peripheral vascular disease, [[thrombosis]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RYTHMOL SR (PROPAFENONE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f | publisher = | date = | accessdate = 13 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Ketones]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Alcohols]]
| |
| [[Category:Amines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |